Inhibition of PI4KIIIα as a Novel Potential Approach for Gaucher Disease Treatment.
作者信息
Zheng Linan, Hong Feng, Huang Fude, Wang Wenan
机构信息
Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
Department of Neurology, Xinhua Hospital Chongming Branch, Shanghai, 202150, China.
出版信息
Neurosci Bull. 2021 Aug;37(8):1234-1239. doi: 10.1007/s12264-021-00704-w. Epub 2021 May 21.
Abstract
摘要
相似文献
1
Inhibition of PI4KIIIα as a Novel Potential Approach for Gaucher Disease Treatment.抑制PI4KIIIα作为戈谢病治疗的一种新型潜在方法。
Neurosci Bull. 2021 Aug;37(8):1234-1239. doi: 10.1007/s12264-021-00704-w. Epub 2021 May 21.
2
Probing the Architecture, Dynamics, and Inhibition of the PI4KIIIα/TTC7/FAM126 Complex.探究 PI4KIIIα/TTC7/FAM126 复合物的结构、动态和抑制作用。
J Mol Biol. 2018 Sep 14;430(18 Pt B):3129-3142. doi: 10.1016/j.jmb.2018.07.020. Epub 2018 Jul 18.
3
Hepatitis C Virus Subverts Human Choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and Upregulates PI4KIIIα Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication.丙型肝炎病毒利用人胆碱激酶α连接磷脂酰肌醇-4-激酶IIIα（PI4KIIIα）和NS5A，并上调PI4KIIIα的激活，从而促进三元复合物转运至内质网进行病毒复制。
J Virol. 2017 Jul 27;91(16). doi: 10.1128/JVI.00355-17. Print 2017 Aug 15.
4
Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.丙型肝炎病毒 NS5A 蛋白与磷脂酰肌醇 4-激酶 IIIα 相互作用并调节病毒复制。
J Biol Chem. 2011 Apr 1;286(13):11290-8. doi: 10.1074/jbc.M110.194472. Epub 2011 Feb 5.
5
The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.脂质激酶磷脂酰肌醇-4 激酶 IIIα调节丙型肝炎病毒 NS5A 的磷酸化状态。
PLoS Pathog. 2013 May;9(5):e1003359. doi: 10.1371/journal.ppat.1003359. Epub 2013 May 9.
6
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.HCV 颠覆了依赖于 PI4KIIIα 的 PI4P 的代谢，而具有抗病毒活性的 4-苯胺基喹唑啉则靶向该代谢途径。
PLoS Pathog. 2012;8(3):e1002576. doi: 10.1371/journal.ppat.1002576. Epub 2012 Mar 8.
7
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.评估磷酸肌醇-4-激酶 IIIα 作为丙型肝炎病毒药物靶点。
J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15.
8
Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha.维持质膜中激素敏感的磷酸肌醇池需要磷脂酰肌醇4激酶IIIα。
Mol Biol Cell. 2008 Feb;19(2):711-21. doi: 10.1091/mbc.e07-07-0713. Epub 2007 Dec 12.
9
A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells.前列腺癌细胞中 CXCR4 和 PI4KIIIα 之间的新型串扰。
Oncogene. 2019 Jan;38(3):332-344. doi: 10.1038/s41388-018-0448-0. Epub 2018 Aug 15.
10
Activity-dependent PI4P synthesis by PI4KIIIα regulates long-term synaptic potentiation.PI4KIIIα 依赖性 PI4P 合成调节长时程突触增强。
Cell Rep. 2022 Mar 1;38(9):110452. doi: 10.1016/j.celrep.2022.110452.
引用本文的文献
1
Phenylarsine oxide inhibits the accumulation of lipid droplets in macrophages.苯胂氧化物抑制巨噬细胞中脂滴的积累。
Acta Biochim Biophys Sin (Shanghai). 2022 Oct 25;54(12):1931-1934. doi: 10.3724/abbs.2022107.
本文引用的文献
1
Tau Accumulation and Defective Autophagy: A Common Pathological Mechanism Underlying Repeat-Expansion-Induced Neurodegenerative Diseases?tau蛋白积累与自噬缺陷：重复序列扩增诱导的神经退行性疾病的共同病理机制？
Neurosci Bull. 2020 Dec;36(12):1411-1413. doi: 10.1007/s12264-020-00605-4. Epub 2020 Nov 5.
2
Inhibition of phosphatidylinositol kinase-III alpha induces or facilitates lysosome exocytosis from microglia.抑制磷脂酰肌醇激酶-IIIα可诱导或促进小胶质细胞溶酶体的胞吐作用。
Neuroreport. 2020 Jul 10;31(10):697-701. doi: 10.1097/WNR.0000000000001348.
3
Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular.溶酶体胞吐作用、外泌体释放和分泌自噬：自噬和内溶酶体系统向细胞外延伸。
Int J Mol Sci. 2020 Apr 8;21(7):2576. doi: 10.3390/ijms21072576.
4
Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases.溶酶体功能障碍与罕见神经退行性疾病中的自噬作用
J Mol Biol. 2020 Apr 3;432(8):2714-2734. doi: 10.1016/j.jmb.2020.02.033. Epub 2020 Mar 5.
5
mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells.mTOR 过度活跃介导戈谢病 iPSC 神经元细胞溶酶体功能障碍。
Dis Model Mech. 2019 Oct 16;12(10):dmm038596. doi: 10.1242/dmm.038596.
6
Lysosomes as a therapeutic target.溶酶体作为治疗靶点。
Nat Rev Drug Discov. 2019 Dec;18(12):923-948. doi: 10.1038/s41573-019-0036-1. Epub 2019 Sep 2.
7
Neuroprotective Autophagic Flux Induced by Hyperbaric Oxygen Preconditioning is Mediated by Cystatin C.高压氧预处理诱导的神经保护自噬流是由胱抑素 C 介导的。
Neurosci Bull. 2019 Apr;35(2):336-346. doi: 10.1007/s12264-018-0313-8. Epub 2018 Dec 5.
8
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.戈谢病的病理生理学、临床表现及治疗综述
Int J Mol Sci. 2017 Feb 17;18(2):441. doi: 10.3390/ijms18020441.
9
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.用于神经元型戈谢病底物还原疗法的可进入中枢神经系统的葡糖神经酰胺合酶抑制剂
Mol Ther. 2016 Jun;24(6):1019-1029. doi: 10.1038/mt.2016.53. Epub 2016 Mar 7.
10
Gaucher Disease: Clinical, Biological and Therapeutic Aspects.戈谢病：临床、生物学及治疗方面
Pathobiology. 2016;83(1):13-23. doi: 10.1159/000440865. Epub 2015 Nov 21.
Zotero 插件